Literature DB >> 3373570

Neutralization of adenoviruses: kinetics, stoichiometry, and mechanisms.

C Wohlfart1.   

Abstract

Kinetic curves for neutralization of adenovirus type 2 with anti-hexon serum revealed no lag periods even when the serum was highly diluted or when the temperature was lowered to 4 degrees C, thus indicating a single-hit mechanism. Multiplicity curves determined with anti-hexon serum displayed a linear correlation between the degree of neutralization and dilution of antiserum. Neutralization values experimentally obtained under steady-state conditions fully fitted a single-hit model based on Poisson calculations. Quantitation of the amount of 125I-labeled type-specific anti-hexon antibodies needed for full neutralization of adenovirus showed that 1.4 antibodies were attached per virion under such conditions. Virions already attached to HeLa cells at 4 degrees C were, to a large extent, neutralizable by anti-hexon serum, whereas anti-fiber and anti-penton base antisera were negative. It is suggested that adenovirus may be neutralized by two pathways: aggregation of the virions (extracellular neutralization) as performed by anti-fiber antibodies and blocking of virion entrance from the acidic endosomes into the cytoplasm (intracellular neutralization). The latter effect could be obtained by (i) covering of the penton bases, as performed by anti-penton base antibodies, thereby preventing interaction between the penton bases and the endosomal membrane, which results in trapping of virions within endosomes, and (ii) inhibition of the low-pH-induced conformational change of the viral capsid, which seems to occur in the endosomes and is necessary for proper exposure of the penton bases, as performed by anti-hexon antibodies.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3373570      PMCID: PMC253388     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  46 in total

1.  IMMUNIZATION OF VOLUNTEERS WITH SOLUBLE ANTIGENS OF ADENOVIRUS TYPE 1.

Authors:  J A KASEL; M HUBER; F LODA; P A BANKS; V KNIGHT
Journal:  Proc Soc Exp Biol Med       Date:  1964-10

2.  THE INTERACTION OF NEWCASTLE DISEASE VIRUS AND NEUTRALIZING ANTIBODY.

Authors:  A GRANOFF
Journal:  Virology       Date:  1965-01       Impact factor: 3.616

3.  Neutralization of viral infectivity: characterization of the virus-antibody complex, including association, dissociation, and host-cell interaction.

Authors:  B MANDEL
Journal:  Ann N Y Acad Sci       Date:  1960-01-13       Impact factor: 5.691

4.  A study of the basic aspects of neutralization of two animal viruses, western equine encephalitis virus and poliomyelitis virus.

Authors:  R DULBECCO; M VOGT; A G STRICKLAND
Journal:  Virology       Date:  1956-04       Impact factor: 3.616

5.  Characterization of type 1 poliovirus by electrophoretic analysis.

Authors:  B Mandel
Journal:  Virology       Date:  1971-06       Impact factor: 3.616

6.  Determination of protein: a modification of the Lowry method that gives a linear photometric response.

Authors:  E F Hartree
Journal:  Anal Biochem       Date:  1972-08       Impact factor: 3.365

7.  Structure and development of viruses as observed in the electron microscope. V. Entry and uncoating of adenovirus.

Authors:  C Morgan; H S Rosenkranz; B Mednis
Journal:  J Virol       Date:  1969-11       Impact factor: 5.103

8.  Synthesis and processing of the precursor to the major core protein of adenovirus type 2.

Authors:  E Everitt; S A Meador; A S Levine
Journal:  J Virol       Date:  1977-01       Impact factor: 5.103

9.  Bivalent attachment of antibody onto poliovirus leads to conformational alteration and neutralization.

Authors:  E A Emini; P Ostapchuk; E Wimmer
Journal:  J Virol       Date:  1983-11       Impact factor: 5.103

10.  Immunization, isolation of immunoglobulins, estimation of antibody titre.

Authors:  N Harboe; A Ingild
Journal:  Scand J Immunol Suppl       Date:  1973
View more
  80 in total

1.  Ovine adenovirus vectors overcome preexisting humoral immunity against human adenoviruses in vivo.

Authors:  C Hofmann; P Löser; G Cichon; W Arnold; G W Both; M Strauss
Journal:  J Virol       Date:  1999-08       Impact factor: 5.103

2.  Hemagglutinin 1-specific immunoglobulin G and Fab molecules mediate postattachment neutralization of influenza A virus by inhibition of an early fusion event.

Authors:  M J Edwards; N J Dimmock
Journal:  J Virol       Date:  2001-11       Impact factor: 5.103

3.  CD4 binding site antibodies inhibit human immunodeficiency virus gp120 envelope glycoprotein interaction with CCR5.

Authors:  Aarti Raja; Miro Venturi; Peter Kwong; Joseph Sodroski
Journal:  J Virol       Date:  2003-01       Impact factor: 5.103

4.  Construction and characterization of adenovirus serotype 5 packaged by serotype 3 hexon.

Authors:  Hongju Wu; Igor Dmitriev; Elena Kashentseva; Toshiro Seki; Minghui Wang; David T Curiel
Journal:  J Virol       Date:  2002-12       Impact factor: 5.103

5.  Neutralizing antibodies and CD8+ T lymphocytes both contribute to immunity to adenovirus serotype 5 vaccine vectors.

Authors:  Shawn M Sumida; Diana M Truitt; Michael G Kishko; Janelle C Arthur; Shawn S Jackson; Darci A Gorgone; Michelle A Lifton; Wouter Koudstaal; Maria G Pau; Stefan Kostense; Menzo J E Havenga; Jaap Goudsmit; Norman L Letvin; Dan H Barouch
Journal:  J Virol       Date:  2004-03       Impact factor: 5.103

6.  Regulation of virus neutralization and the persistent fraction by TRIM21.

Authors:  W A McEwan; F Hauler; C R Williams; S R Bidgood; D L Mallery; R A Crowther; L C James
Journal:  J Virol       Date:  2012-05-30       Impact factor: 5.103

7.  Functional genetic and biophysical analyses of membrane disruption by human adenovirus.

Authors:  Crystal L Moyer; Christopher M Wiethoff; Oana Maier; Jason G Smith; Glen R Nemerow
Journal:  J Virol       Date:  2011-01-05       Impact factor: 5.103

8.  Structural and functional determinants in adenovirus type 2 penton base recombinant protein.

Authors:  L Karayan; S S Hong; B Gay; J Tournier; A D d'Angeac; P Boulanger
Journal:  J Virol       Date:  1997-11       Impact factor: 5.103

9.  Identification of adenovirus (ad) penton base neutralizing epitopes by use of sera from patients who had received conditionally replicative ad (addl1520) for treatment of liver tumors.

Authors:  Saw See Hong; Nagy A Habib; Laure Franqueville; Steen Jensen; Pierre A Boulanger
Journal:  J Virol       Date:  2003-10       Impact factor: 5.103

10.  Encapsulation of Adenovirus BMP2-Transduced Cells with PEGDA Hydrogels Allows Bone Formation in the Presence of Immune Response.

Authors:  Pedro Alvarez-Urena; Eleanor Davis; Corinne Sonnet; Gabrielle Henslee; Zbigniew Gugala; Edward V Strecker; Laura J Linscheid; Maude Cuchiara; Jennifer West; Alan Davis; Elizabeth Olmsted-Davis
Journal:  Tissue Eng Part A       Date:  2017-01-25       Impact factor: 3.845

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.